alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-32

        SECTION 1350 CERTIFICATION OF DAVID F. LEVY AND RICHARD DEA

                         SECTION 1350 CERTIFICATION

In connection with the quarterly report of InZon Corporation
(formerly W-J International, Ltd.) ("Company") on Form 10-QSB for the
quarter ended December 31, 2004 as filed with the Securities and
Exchange Commission ("Report"), the undersigned, in the capacities and
on the dated indicated below, hereby certify pursuant to Section 906
of the Sarbanes-Oxley Act of 2003 (18 U.S.C. Section 1350) that to
their knowledge:

1.  The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

2.  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.


Dated: February 11, 2005               By: /s/ David F. Levy
                                       David F. Levy, President


Dated: February 11, 2005               By: /s/ Richard Dea
                                       Richard Dea, Chief Financial Officer
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.6350 Ultraviolet detector. ( a ) *Identification.* An ultraviolet detector is a device intended to provide a source of ultraviolet light which is used to identify otherwise invisible material, such as dental plaque, present in or on teeth.
( b ) *Classification.* Class II.
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3000 Bone cap. ( a ) *Identification.* A bone cap is a mushroom-shaped device intended to be implanted made of either silicone elastomer or ultra-high molecular weight polyethylene. It is used to cover the severed end of a long bone, such as the humerus or tibia, to control bone overgrowth in juvenile amputees.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 888.9.
[52 FR 33702, Sept. 4, 1987, as amended at 61 FR 1124, Jan. 16, 1996; 66 FR 38815, July 25, 2001]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                             694
<SECURITIES>                                         0
<RECEIVABLES>                                    5,984
<ALLOWANCES>                                       180
<INVENTORY>                                      6,198
<CURRENT-ASSETS>                                13,812
<PP&E>                                           3,946
<DEPRECIATION>                                   3,078
<TOTAL-ASSETS>                                  18,490
<CURRENT-LIABILITIES>                           11,095
<BONDS>                                              0
<PREFERRED-MANDATORY>                              276
<PREFERRED>                                        938
<COMMON>                                            68
<OTHER-SE>                                       4,304
<TOTAL-LIABILITY-AND-EQUITY>                    18,490
<SALES>                                         19,559
<TOTAL-REVENUES>                                19,559
<CGS>                                           10,645
<TOTAL-COSTS>                                    7,695
<OTHER-EXPENSES>                                 (381)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 263
<INCOME-PRETAX>                                  1,337
<INCOME-TAX>                                        13
<INCOME-CONTINUING>                              1,324
<DISCONTINUED>                                   (910)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       414
<EPS-BASIC>                                      0.020
<EPS-DILUTED>                                    0.020


</TABLE>
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.5850 Powered muscle stimulator. ( a ) *Identification.* A powered muscle stimulator is an electrically powered device intended for medical purposes that repeatedly contracts muscles by passing electrical currents through electrodes contacting the affected body area.
( b ) *Classification.* Class II (performance standards).
Exhibit 32.1



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002



In connection with the Annual Report of
Borqs Technologies, Inc. (the “Company”) on Form 10-K/A for the fiscal year ended December 31, 2017, as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on
the dates indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that to the best of his knowledge:



|1. | The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or
78o(d)); and
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------



|2. | The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------



Date: May 14, 2018



| | /s/ Pat Sek Yuen Chan        
| | -----------------------------
| | Pat Sek Yuen Chan            
| | Chief Executive Officer      
| | (Principal Executive Officer)
**Exhibit 23.1**
**Consent of Independent Auditors**
We consent to the incorporation by reference in the Registration Statements(Form S-8 No. 333-13405 and No. 333-81023) pertaining to the Amended andRestated 1995 Equity Participation Plan of Ambassadors International, Inc. ofour report dated February 13, 2004, with respect to the consolidated financialstatements of Ambassadors International, Inc. included in the Annual Report(Form 10-K) for the year ended December 31, 2003.
Our audits also included the information as of and for the years ended December31, 2003 and 2002 included in the financial statement schedule of AmbassadorsInternational, Inc. listed in Item 15(a). This schedule is the responsibilityof the Company’s management. Our responsibility is to express an opinion basedon our audits. In our opinion, the financial statement schedule referred toabove, when considered in relation to the basic financial statements taken as awhole, presents fairly in all material respects the information set forththerein.
           /s/ Ernst & Young LLP
Irvine, California
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act). The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce for commercial distribution the device when: ( a ) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device; e.g., the device is intended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;
( b ) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or identifies infectious agents by using deoxyribonucleic acid (DNA) probe or nucleic acid hybridization technology rather than culture or immunoassay technology; or
( c ) The device is an in vitro device that is intended: ( 1 ) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices;
( 2 ) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism;
( 3 ) For measuring an analyte that serves as a surrogate marker for screening, diagnosis, or monitoring life-threatening diseases such as acquired immune deficiency syndrome (AIDS), chronic or active hepatitis, tuberculosis, or myocardial infarction or to monitor therapy;
( 4 ) For assessing the risk of cardiovascular diseases;
( 5 ) For use in diabetes management;
( 6 ) For identifying or inferring the identity of a microorganism directly from clinical material;
( 7 ) For detection of antibodies to microorganisms other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used to determine immunity, or the assay is intended for use in matrices other than serum or plasma;
( 8 ) For noninvasive testing as defined in § 812.3(k) of this chapter; and
( 9 ) For near patient testing (point of care).
[65 FR 2314, Jan. 14, 2000]
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1997
<CASH>                                       4,449,850
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0<F1>
<PP&E>                                     456,623,162
<DEPRECIATION>                              23,166,762
<TOTAL-ASSETS>                             445,292,524
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                   346,306,618
<OTHER-SE>                                (30,502,348)
<TOTAL-LIABILITY-AND-EQUITY>               445,292,524
<SALES>                                              0<F2>
<TOTAL-REVENUES>                            50,231,191
<CGS>                                                0
<TOTAL-COSTS>                               33,208,898
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           4,840,391
<INCOME-PRETAX>                             13,867,890
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         13,867,890
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                13,867,890
<EPS-PRIMARY>                                     0.44
<EPS-DILUTED>                                        0
<FN>
<F1>Current Assets and Current Liabilities are not separated to conform
with industry standards.
<F2>Income is from rental income. There are no Sales or Cost of Goods
Sold.
</FN>
        

</TABLE>
EX-31Rule 13a-14(d)/15d-14(d) Certifications.

 

 

I,Anthony Sfarra, certify that:

 

1. Ihave reviewed this report on Form 10-K and all reports on Form 10-D required tobe filed in respect of the period covered by this report on Form 10-K of theWells Fargo Commercial Mortgage Trust 2015-SG1 (the "Exchange Act periodicreports");

 

2.Based on my knowledge, the Exchange Act periodic reports, taken as a whole, donot contain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

 

3. Basedon my knowledge, all of the distribution, servicing and other informationrequired to be provided under Form 10-D for the period covered by this reportis included in the Exchange Act periodic reports;

 

4.Based on my knowledge and the servicer compliance statements required in thisreport under Item 1123 of Regulation AB, and except as disclosed in theExchange Act periodic reports, the servicers have fulfilled their obligationsunder the servicing agreements in all material respects; and

 

5. Allof the reports on assessment of compliance with servicing criteria forasset-backed securities and their related attestation reports on assessment ofcompliance with servicing criteria for asset-backed securities required to beincluded in this report in accordance with Item 1122 of Regulation AB andExchange Act Rules 13a-18 and 15d-18 have been included as an exhibit to thisreport, except as otherwise disclosed in this report. Any material instances ofnoncompliance described in such reports have been disclosed in this report onForm 10-K.

 

Ingiving the certifications above, I have reasonably relied on informationprovided to me by the following unaffiliated parties:

 

RialtoCapital Advisors, LLC, as Special Servicer, Wilmington Trust, NationalAssociation, as Trustee, BellOak, LLC, as Trust Advisor, CoreLogicSolutions, LLC, as Servicing Function Participant,PGIM Real Estate Loan Services, Inc. (formerly known as Prudential AssetResources, Inc.), as Primary Servicer, Computershare Trust Company, NationalAssociation, as Servicing Function Participant for the CertificateAdministrator, and Computershare Trust Company, National Association, asServicing Function Participant for the Custodian.

 

 

 

Dated: March 15, 2024

 

 

/s/Anthony Sfarra

AnthonySfarra 

President

(seniorofficer in charge of securitization of the depositor)
EX-10.1



 Exhibit 10.1 

FIRST AMENDMENT 
 TO THE

 PAYCOM SOFTWARE, INC. 

2014 LONG-TERM INCENTIVE PLAN 

This FIRST AMENDMENT TO THE PAYCOM SOFTWARE, INC. 2014 LONG-TERM INCENTIVE PLAN (this “Amendment”), dated as of
March 28, 2017, is made and entered into by Paycom Software, Inc., a Delaware corporation (the “Company”), subject to approval by the Company’s stockholders. Terms used in this Amendment with initial capital letters
that are not otherwise defined herein shall have the meanings ascribed to such terms in the Paycom Software, Inc. 2014 Long-Term Incentive Plan (the “Plan”). 

RECITALS 
 WHEREAS,
Article 9 of the Plan provides that the Board of Directors of the Company (the “Board”) may amend the Plan at any time and from time to time; 

WHEREAS, the Board desires to amend the Plan to increase the number of shares of Common Stock that may be delivered pursuant to Awards
under the Plan by an additional two million (2,000,000) shares, for an aggregate maximum total of thirteen million three hundred fifty thousand eight hundred eighty-one (13,350,881) shares available under the Plan; and 

WHEREAS, as of the date hereof, the Board resolved that the Plan be amended to increase the number of shares that may be delivered
pursuant to Awards under the Plan by an additional two million (2,000,000) shares. 
 NOW, THEREFORE, in accordance with Article
9 of the Plan, the Company hereby amends the Plan, effective as of the date hereof, as follows: 
 1. Section 5.1 of the Plan is hereby
amended by deleting said section in its entirety and substituting in lieu thereof the following new Section 5.1: 

5.1 Number Available for Awards. Subject to adjustment as provided in Articles 11 and 12, the maximum number of
shares of Common Stock that may be delivered pursuant to Awards granted under the Plan is thirteen million three hundred fifty thousand eight hundred eighty-one (13,350,881) shares, of which one hundred percent (100%) may be delivered
pursuant to Incentive Stock Options. Subject to adjustment pursuant to Articles 11 and 12, the maximum number of shares of Common Stock with respect to which Stock Options or SARs may be granted to an Executive Officer during any calendar
year is five million three hundred twenty-three thousand nine hundred and seven (5,323,907) shares of Common Stock. Shares to be issued may be made available from authorized but unissued Common Stock, Common Stock held by the Company in its
treasury, or Common Stock purchased by the Company on the open market or otherwise. During the term of this Plan, the Company will at all times reserve and keep available the number of shares of Common Stock that shall be sufficient to satisfy the
requirements of this Plan. 
 2. Except as expressly amended by this Amendment, the Plan shall continue in full force and effect in
accordance with the provisions thereof. 
 * * * * * * * * 







 IN WITNESS WHEREOF, the Company has caused this Amendment to be duly executed as of the
date first written above. 
  
  

			
	PAYCOM SOFTWARE, INC.
		
	By:	 	/s/ Chad Richison
	Name:	 	Chad Richison
	Title:	 	Chief Executive Officer
# C_2016038EN.01005501.xml

| 1.2.2016 | EN | Official Journal of the European Union | C 38/55 |
| --- | --- | --- | --- |

1.2.2016

EN

Official Journal of the European Union

C 38/55

---

Order of the General Court of 23 November 2015 — EREF v Commission

(Case T-694/14) (1)

1

((Action for annulment - Guidelines on State aid for environmental protection and energy 2014-2020 - Association - Members not directly concerned - Inadmissibility))

(2016/C 038/72)

Language of the case: English

Parties

Parties

Applicant: European Renewable Energies Federation (EREF) (Brussels, Belgium) (represented by: U. Prall, lawyer)

Applicant:

Defendant: European Commission (represented by: L. Flynn, K. Herrmann and R. Sauer, acting as Agents)

Defendant:

Re:

Re:

ACTION for the annulment of the Communication from the Commission of 28 June 2014, entitled ‘Guidelines on State aid for environmental protection and energy 2014-2020’ (OJ 2014 C 200, p. 1), concerning the assessment criteria of the compatibility with the internal market of State aid for energy from renewable sources.

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as inadmissible. |
| --- | --- |

1.

The action is dismissed as inadmissible.

| 2. | European Renewable Energies Federation (EREF) shall pay its own costs and those incurred by the European Commission. |
| --- | --- |

2.

European Renewable Energies Federation (EREF) shall pay its own costs and those incurred by the European Commission.

---

(1)  OJ C 409, 17.11.2014.

1

---
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.2377 Apnea monitor. ( a ) *Identification.* An apnea monitor is a complete system intended to alarm primarily upon the cessation of breathing timed from the last detected breath. The apnea monitor also includes indirect methods of apnea detection such as monitoring of heart rate and other physiological parameters linked to the presence or absence of adequate respiration.
( b ) *Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Apnea Monitors; Guidance for Industry and FDA.”
[67 FR 46852, July 17, 2002]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4010 Tissue adhesive. ( a ) *Tissue adhesive for the topical approximation of skin* — ( 1 ) *Identification.* A tissue adhesive for the topical approximation of skin is a device intended for topical closure of surgical incisions, including laparoscopic incisions, and simple traumatic lacerations that have easily approximated skin edges. Tissue adhesives for the topical approximation of skin may be used in conjunction with, but not in place of, deep dermal stitches.
( 2 ) *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: “Tissue Adhesive for the Topical Approximation of Skin.” See § 878.1(e) of this chapter for the availability of this guidance document.
( b ) *Tissue adhesive for non-topical use* — ( 1 ) *Identification.* A tissue adhesive for non-topical use, including adhesives intended for use in the embolization of brain arteriovenous malformation or for use in ophthalmic surgery, is a device used for adhesion of internal tissues and vessels.
( 2 ) *Classification.* Class III (premarket approval). As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed. See § 878.3 of this chapter.
[73 FR 31033, May 30, 2008]
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1275 Electroconductive media. ( a ) *Identification.* Electroconductive media are the conductive creams or gels used with external electrodes to reduce the impedance (resistance to alternating current) of the contact between the electrode surface and the skin.
( b ) *Classification.* Class II (performance standards).
# United States Department of the Interior

NATIONAL PARK SERVICE

Air Resources Division

P.O. Box 25287

Denver, Colorado 80225

April 27, 2016

Mr. Lew Weinstock

U.S. Environmental Protection Agency

Research T riangle Park, NC 27709

Room C304

- 02

Re: Certification of National Park Service, Gaseous Pollutant Monitoring Progr am Data for 2015

Dear Mr. Weinstock,

The National Park Service, Air Resources Division, hereby certifies the NPS Gaseous Pollut ant Mon itoring

Program (GPMP) ozone data fo r the year 2015 that currentl y reside on the EPA AQS. The ambient concentration data

and associated quality assurance data have been completely submitted to AQS for the year 2015

. T hese data have

undergone stringent vali dation procedures and are believed to be a consistent and accurate representation of ambient air

quality conditions within the monitored NPS units. All quality assurance findings have been taken into account in

determining the data’s validity.

Attached ar e:

• A summary table of NPS units that the NPS intends to certify for 2015.

• AMP600 Data Certification Report for 2015 data

.

Please refer to the attached summary table that lists which sites the NPS intends to certify. There are sites

operated by the NPS that we do not wish to certify because of the method used or because the site does not belong

solely to the NPS

. These sites are not included in the table

. Please contact me (barkley_sive@nps.gov; 303

- 987

- 6947 ) if

you have any questions.

Sinc erely,

Barkley Sive

BS :jw Program Manager

Cc: John Vimont

Kristi Morris